Research article · 27 Jul 2026
Conference abstractPublished 17 Nov 2015
Supergenerics: Esomeprazole minitablets as a model
Yarmouk University, Jordan
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Esomeprazole is the S-isomer of omeprazole. It is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of (H+/K+) ATPase in gastric parietal cell. It is marketed by Astrazeneca Co., under the brand name NexiumÃ?® 20 mg and 40 mg as gastro-resistant film coated pellets compressed to tablets (MUPS). Generic products are identical drugs with the brand name drug and are interchangeable with them, and they are therapeutically equivalent. US FDA and other similar authorities do not recognize the term âÂ?Â?âÂ?Â?SupergenericsâÂ?Â?âÂ?Â?. These products are also referred as âÂ?Â?added value generics, new therapeutic entities or hybridsâÂ?Â?. These products differ from the original product in formulation or method of delivery. Moreover, these products could be an improved formulation of a known product. A pharmaceutical product developed and manufactured with less excipients and unit operation while maintaining the product therapeutic performance compared to the originator could be considered as an improved therapeutic entity as it reduces the overall cost for manufacturing that could lead to reduced healthcare spending. In this study, enteric coated mini-tablets of ESM were prepared. Bioequivalence studies both under fed and fasting conditions were carried out for the minitablets 40 mg versus Nexium 40 mg MUPS. The results for fasting conditions were within acceptable limits, while fed conditions results were not (higher extent of absorption which means less in vivo degradation than Nexium). The argument of this presentation: Do we accept or reject, particularly when it has no negative effect on the therapeutic efficacy?
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Clinical Pharmacology & Biopharmaceutics.
Article · 20 Jul 2026
Population Pharmacology: Precision Dosing for Diverse Patients
Article · 17 Jul 2026
Therapeutic Drug Monitoring: Optimizing Therapy, Minimizing Toxicity
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Pharmacology & Biopharmaceutics
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Derar Omari”
